Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells

A large number of genetic variants have been associated with human diseases. However, the lack of a genetic diversification approach has impeded our ability to interrogate functions of genetic variants in mammalian cells. Current screening methods can only be used to disrupt a gene or alter its expression. Here we report the fusion of activation-induced cytidine deaminase (AID) with nuclease-inactive clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (dCas9) for efficient genetic diversification, which enabled high-throughput screening of functional variants. Guided by single guide (sg)RNAs, dCas9-AID-P182X (AIDx) directly changed cytidines or guanines to the other three bases independent of AID hotspot motifs, generating a large repertoire of variants at desired loci. Coupled with a uracil-DNA glycosylase inhibitor, dCas9-AIDx converted targeted cytidines specifically to thymines, creating specific point mutations. By targeting BCR-ABL with dCas9-AIDx, we efficiently identified known and new mutations conferring imatinib resistance in chronic myeloid leukemia cells. Thus, targeted AID-mediated mutagenesis (TAM) provides a forward genetic tool to screen for gain-of-function variants at base resolution.

[1]  Albert J R Heck,et al.  Structural basis for CRISPR RNA-guided DNA recognition by Cascade , 2011, Nature Structural &Molecular Biology.

[2]  G. Church,et al.  Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.

[3]  Jay Shendure,et al.  Saturation Editing of Genomic Regions by Multiplex Homology-Directed Repair , 2014, Nature.

[4]  A. Ullrich,et al.  Strategies to overcome resistance to targeted protein kinase inhibitors , 2004, Nature Reviews Drug Discovery.

[5]  Eric S. Lander,et al.  Direct Identification of Hundreds of Expression-Modulating Variants using a Multiplexed Reporter Assay , 2016, Cell.

[6]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[7]  M. Fenner,et al.  CRISPR--a widespread system that provides acquired resistance against phages in bacteria and archaea. , 2007 .

[8]  Alberto Martin,et al.  Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas , 2002, Nature.

[9]  Vasco M. Barreto,et al.  C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. , 2003, Molecular cell.

[10]  David R. Liu,et al.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage , 2016, Nature.

[11]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[12]  Sergio Roa,et al.  The biochemistry of somatic hypermutation. , 2008, Annual review of immunology.

[13]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[14]  David R. Liu,et al.  A System for the Continuous Directed Evolution of Biomolecules , 2011, Nature.

[15]  Virginia W Cornish,et al.  A Heritable Recombination system for synthetic Darwinian evolution in yeast. , 2012, ACS synthetic biology.

[16]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[17]  T. Honjo,et al.  AID Enzyme-Induced Hypermutation in an Actively Transcribed Gene in Fibroblasts , 2002, Science.

[18]  M. Lieber,et al.  R-loops at immunoglobulin class switch regions in the chromosomes of stimulated B cells , 2003, Nature Immunology.

[19]  Dan S. Tawfik,et al.  Man-made cell-like compartments for molecular evolution , 1998, Nature Biotechnology.

[20]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[21]  Patrick C. Wilson,et al.  Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation , 2005, The Journal of experimental medicine.

[22]  G Vergnaud,et al.  CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. , 2005, Microbiology.

[23]  Yolanda Schaerli,et al.  Evolution of enzyme catalysts caged in biomimetic gel-shell beads. , 2014, Nature chemistry.

[24]  M. Neuberger,et al.  Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase , 2002, Nature.

[25]  Matthew C. Canver,et al.  Analyzing CRISPR genome-editing experiments with CRISPResso , 2016, Nature Biotechnology.

[26]  C. E. Schrader,et al.  Mutations occur in the Ig Sμ region but rarely in Sγ regions prior to class switch recombination , 2003, The EMBO journal.

[27]  Chibo Hong,et al.  The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer , 2015, Science.

[28]  George Georgiou,et al.  Engineering of TEV protease variants by yeast ER sequestration screening (YESS) of combinatorial libraries , 2013, Proceedings of the National Academy of Sciences.

[29]  M. Lieber,et al.  Fine-Structure Analysis of Activation-Induced Deaminase Accessibility to Class Switch Region R-Loops , 2005, Molecular and Cellular Biology.

[30]  J. García-Martínez,et al.  Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic Elements , 2005, Journal of Molecular Evolution.

[31]  Y. Gondo,et al.  Mutational pattern and frequency of induced nucleotide changes in mouse ENU mutagenesis , 2007, BMC Molecular Biology.

[32]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[33]  M. Nachman,et al.  Estimate of the mutation rate per nucleotide in humans. , 2000, Genetics.

[34]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[35]  T. Honjo,et al.  Separate domains of AID are required for somatic hypermutation and class-switch recombination , 2004, Nature Immunology.

[36]  J. Tainer,et al.  Crystal structure of human uracil-DNA glycosylase in complex with a protein inhibitor: Protein mimicry of DNA , 1995, Cell.

[37]  M. Neuberger,et al.  Molecular mechanisms of antibody somatic hypermutation. , 2007, Annual review of biochemistry.

[38]  P. Lipsky,et al.  Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands , 1998, European journal of immunology.

[39]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[40]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[41]  G. Daley,et al.  Mechanisms and implications of imatinib resistance mutations in BCR-ABL , 2004, Current opinion in hematology.

[42]  Rocco Piazza,et al.  Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. , 2003, The Lancet. Oncology.